Tag: John Glen

  • John Glen – 2016 Parliamentary Question to the Department of Health

    John Glen – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2016-02-29.

    To ask the Secretary of State for Health, what discussions NICE has had with the EU institutions on the proposed Joint Action 3 on health technology appraisals.

    George Freeman

    In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).

    NICE has advised that it has had a number of discussions with European Commission officials, as well as other partner organisations, about NICE’s participation in this planned Joint Action.

    The Department is responsible for the policy framework for the assessment of health technologies and officials remain in close contact with NICE regarding the European Union collaboration in HTA, including the proposals for the production of joint products as part of the third Joint Action.

  • John Glen – 2016 Parliamentary Question to the Department for Education

    John Glen – 2016 Parliamentary Question to the Department for Education

    The below Parliamentary question was asked by John Glen on 2016-09-05.

    To ask the Secretary of State for Education, whether her Department holds data on the (a) use and (b) prevalence of setting and streaming in schools in England.

    Nick Gibb

    In-school organisation, such as streaming or setting, is a matter for individual schools, and data is not collected or held by the Department on this matter.

  • John Glen – 2016 Parliamentary Question to the Department of Health

    John Glen – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2016-02-29.

    To ask the Secretary of State for Health, what representations he has received from NICE on the potential merits of a European relative effectiveness assessment to inform health technology appraisals.

    George Freeman

    In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).

    NICE has advised that it has had a number of discussions with European Commission officials, as well as other partner organisations, about NICE’s participation in this planned Joint Action.

    The Department is responsible for the policy framework for the assessment of health technologies and officials remain in close contact with NICE regarding the European Union collaboration in HTA, including the proposals for the production of joint products as part of the third Joint Action.

  • John Glen – 2016 Parliamentary Question to the Department of Health

    John Glen – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2016-10-11.

    To ask the Secretary of State for Health, what plans (a) NICE and (b) NHS England has to issue a consultation on changes to the highly specialised technologies evaluation programme.

    Nicola Blackwood

    The National Institute for Health and Care Excellence and NHS England launched a joint consultation on 13 October 2016 setting out proposed changes to the arrangements for the evaluation and adoption of new technologies, including on the methodology for the evaluation of highly specialised technologies.

  • John Glen – 2016 Parliamentary Question to the Department of Health

    John Glen – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2016-02-29.

    To ask the Secretary of State for Health, what discussions he has had with NICE on its policy on a European relative effectiveness assessment for new drugs.

    George Freeman

    In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).

    NICE has advised that it has had a number of discussions with European Commission officials, as well as other partner organisations, about NICE’s participation in this planned Joint Action.

    The Department is responsible for the policy framework for the assessment of health technologies and officials remain in close contact with NICE regarding the European Union collaboration in HTA, including the proposals for the production of joint products as part of the third Joint Action.

  • John Glen – 2016 Parliamentary Question to the Department of Health

    John Glen – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2016-10-11.

    To ask the Secretary of State for Health, whether he plans to appeal NICE’s draft guidance on asfotase alfa for treating paediatric-onset hypophosphatasia, issued in September 2016.

    Nicola Blackwood

    The National Institute for Health and Care Excellence (NICE) is currently evaluating the costs and benefits of asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia to determine whether it can be recommended for national commissioning by NHS England.

    There has not yet been an opportunity for stakeholders to appeal NICE’s recommendations on the use of asfotase alfa for treating paediatric-onset hypophosphatasia. NICE published a second iteration of draft guidance for consultation on 22 September 2016 and the closing date for comments was 13 October 2016. NICE’s independent Evaluation Committee will now consider the comments received in response to the consultation before deciding on the next steps for the evaluation.

  • John Glen – 2016 Parliamentary Question to the Department of Health

    John Glen – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2016-02-29.

    To ask the Secretary of State for Health, how many hospital admissions due to liver disease there were in (a) England and (b) each parliamentary constituency in the last year for which figures are available.

    Jane Ellison

    The information requested is in the attached table.

  • John Glen – 2016 Parliamentary Question to the Department of Health

    John Glen – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2016-10-11.

    To ask the Secretary of State for Health, what steps his Department is taking to ensure that asfotase alfa is available on the NHS to all patients who may benefit from it.

    Nicola Blackwood

    The National Institute for Health and Care Excellence (NICE) is currently evaluating the costs and benefits of asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia to determine whether it can be recommended for national commissioning by NHS England.

    There has not yet been an opportunity for stakeholders to appeal NICE’s recommendations on the use of asfotase alfa for treating paediatric-onset hypophosphatasia. NICE published a second iteration of draft guidance for consultation on 22 September 2016 and the closing date for comments was 13 October 2016. NICE’s independent Evaluation Committee will now consider the comments received in response to the consultation before deciding on the next steps for the evaluation.

  • John Glen – 2016 Parliamentary Question to the Department of Health

    John Glen – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2016-02-29.

    To ask the Secretary of State for Health, what the total cost of treating liver disease was in (a) England and (b) each parliamentary constituency in the last year for which figures are available.

    Jane Ellison

    Information on the total cost of treating liver disease in England and in each parliamentary constituency is not available centrally.

    Such information as is available is from reference costs, which are the average unit cost to National Health Service hospital trusts of providing defined services to patients in a given financial year. Reference costs for acute care are collected by Healthcare Resource Group (HRG), which are standard groupings of similar treatments that use similar resources. HRGs are organised by chapters and sub-chapters, representing different body systems, and HRG sub-chapter GC describes hepatobiliary and pancreatic system disorders. The total costs in the following table, calculated from the national average unit costs and activity submitted in reference costs, will therefore include the costs to NHS hospitals of treating liver and liver related diseases, but also the costs of other related disorders.

    Estimated total costs (£ millions) to NHS hospitals of treating hepatobiliary and pancreatic system disorders, 2014-15

    Liver failure disorders

    £17.7 million

    Malignant, hepatobiliary or pancreatic disorders

    £54.3 million

    Non-malignant, hepatobiliary or pancreatic disorders

    £328.1 million

    Total costs

    £400.0 million

    Source: reference costs, Department of Health

    Notes:

    1. The following HRGs are included in the table:

    Liver Failure Disorders with Multiple Interventions

    Liver Failure Disorders with Single Intervention

    Liver Failure Disorders without Interventions, with CC (Complication and Comorbidity) Score 5+

    Liver Failure Disorders without Interventions, with CC Score 0-4

    Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions

    Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 5+

    Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 2-4

    Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 0-1

    Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 6+

    Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 3-5

    Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 1-2

    Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 0

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 9+

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 4-8

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 0-3

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 9+

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 4-8

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 0-3

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 8+

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 5-7

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 2-4

    Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 0-1

    1. These HRGs are common groupings of the International Classification of Disease (ICD-10) codes used to count the number of finished admission episodes with a primary or secondary diagnosis of liver disease or liver related disease. They also include other ICD-10 codes.

  • John Glen – 2016 Parliamentary Question to the Department for Communities and Local Government

    John Glen – 2016 Parliamentary Question to the Department for Communities and Local Government

    The below Parliamentary question was asked by John Glen on 2016-10-18.

    To ask the Secretary of State for Communities and Local Government, what recent steps his Department has taken to help rough sleepers and homeless people.

    Mr Marcus Jones

    One person without a home is one too many. That is why we launched a new £40 million Homelessness Prevention programme to tackle homelessness and rough sleeping.

    This will enable authorities to support vulnerable people, preventing them from becoming homeless, and ensuring those who do have somewhere safe to stay.